Indiana State Fair victims fund continues to grow
The Central Indiana Community Foundation’s State Fair Remembrance Fund is on pace to raise hundreds of thousands of dollars for victims of the stage collapse.
The Central Indiana Community Foundation’s State Fair Remembrance Fund is on pace to raise hundreds of thousands of dollars for victims of the stage collapse.
Mayor Jerry Sanders likes Indianapolis' blue print of connecting Lucas Oil Stadium to the Indiana Convention Center. Others in San Diego dislike the idea of following Indianapolis' and Indiana's taxpayer-fueled stadium financing plan.
Auditors are reviewing whether Ener1 Inc., which has hundreds of workers in the Indianapolis area, has enough cash to continue operations.
If Peyton Manning isn't ready to start the regular season, Brett Favre would be a guy who could keep the team's Super Bowl hopes alive this year.
Remember when physicians were highly suspicious of retail clinics in drugstores' stealing business from them? Well, now that docs are employed by hospitals, the clinics are being embraced. Indiana University Health announced last week that its physicians will serve as medical directors for 19 MinuteClinic locations, including 17 in the Indianapolis area, one in Bloomington and one in West Lafayette. The clinics are in CVS drugstores, as the company is a subsidiary of Rhode Island-based CVS Caremark Corp. Signs at the clinics will indicate the affiliation with IU Health. The organizations are linking their electronic medical record systems so that, with patient permission, records could be transferred easily from MinuteClinic to an IU Health physician, especially for patients needing more care than MinuteClinic can provide. However, MinuteClinic nurse practitioners will also send patient records to non-IU Health physicians if the patient wishes. The IU Health deal is the 11th hospital partnership signed by MinuteClinic across the country.
Eli Lilly and Co. could get an earlier-than-expected ruling from the U.S. Food and Drug Administration on its once-weekly version of Byetta. The FDA said it would render a decision on the new diabetes drug, called Bydureon, by Jan. 28, Lilly announced last week along with its partners, California-based Amylin Pharmaceuticals Inc. and Massachusetts-based Alkermes Inc. Bydureon would be a once-weekly injection of exenatide, the same compound in Byetta, which currently requires twice-daily injections. Byetta has proved effective at controlling blood sugar and even helping some patients lose weight. But concerns about it include causing pancreas problems and then competition from a similar once-daily drug called Victoza, launched by Denmark-based Novo Nordisk A/S. Lilly expected to receive approval for Bydureon in 2010, but the FDA required another study to test its effects on patients’ heart rhythms. When the new requirement was announced in October, Lilly said it expected approval of Bydureon to be delayed until mid-2012. Worldwide Byetta sales last year totaled $710 million.
A $10 million research endowment at the Eugene and Marilyn Glick Eye Institute has attracted seven new researchers to the Indiana University School of Medicine’s Ophthalmology Department. The department will move this month to a new building at 1160 W. Michigan St. The Glicks pledged a total of $30 million to the medical school—including $20 million that went toward the 80,000-square-foot building, which will house clinical research space, a full-service optical shop and the ophthalmology outpatient clinic. The clinic, which is moving from University Hospital, will double in size. The local philanthropists hoped their gift would vault IU into the top 10 for research and prevention of eye disease.
Strong winds caused the stage rigging for an outdoor concert to collapse, trapping fans.
Revised Insurance Department data show the Indianapolis-based carrier claims about 60 percent of the individual health insurance market in Indiana, down from a previously reported 65 percent.
IU Health Morgan Hospital sued Dr. Dianna Boyer on Aug. 3 to stop her from moving her practice to a facility Franciscan St. Francis Health is building in Martinsville.
Indianapolis’ second-largest law firm could complete a deal with Minneapolis-based Faegre & Benson LLP in October. A need to get larger and to establish a regional presence is fueling the talks.
While we at the Indianapolis Rowing Center applaud Bill Benner’s [July 23 column] call for attention to the crumbling infrastructure of our city’s amateur sports facilities, we’d like to add one bright spot—the rowing center.
A proposal in front of a City-County Council committee would require ticket brokers to purchase an annual license to sell tickets within one mile of an event venue.
A WXIN-TV Channel 59 report suggests the city of Carmel hired private investigators to tail Steven Libman, who resigned abruptly last month as CEO of the Center for the Performing Arts in Carmel.
Researchers at the Indiana University School of Medicine plan to launch a large clinical trial of an experimental two-drug combination for treating late-stage ovarian cancer. The drug combo produced a positive effect in 70 percent of patients in a Phase 2 trial and the IU researchers said they may have discovered biomarkers that could help identify women who would respond best to the therapy. The therapy combines two chemotherapy agents, decitabine with carboplatin. The IU researchers, led by Dr. Daniela Matei, are using it for women who have become resistant to carboplatin after multiple rounds of chemotherapy. IU is now seeking grant funding for a Phase 3 trial, in which the combo therapy will be compared against other approved therapies for ovarian cancer. Their research has been supported by the National Institutes of Health, National Cancer Institute, Walther Cancer Foundation in Indianapolis and the Ovarian Cancer Research Foundation.
DePuy Orthopaedics Inc. plans to spend $27 million on manufacturing and research equipment to grow its orthopedic implant operation in Warsaw, Ind. The expansion will add no jobs to DePuy’s 1,100-person work force, but the Warsaw City Council has approved a 10-year property tax abatement on the equipment. DePuy spokeswoman Jessica Masuga told The Journal Gazette of Fort Wayne that the equipment will improve efficiency. DePuy is a subsidiary of New Jersey-based Johnson & Johnson.
West Lafayette-based Endocyte Inc. raised about $66.8 million in a secondary public offering of nearly 6.7 million shares of company stock. Shares for the offering, which began in mid-July, were priced at $12.26 each. Endocyte, which also has offices in Indianapolis, said it intends to seek permission to sell its ovarian cancer drug in Europe on a limited basis. The decision to proceed came after consultation with the European Medicines Agency and written advice from the regulators, Endocyte said in April. Endocyte shares had more than doubled in price after its initial public offering in February, before sliding in the recent market-wide decline in stocks.
Rochester Medical Implants will move its 28 employees from Rochester to Noblesville. Fulton Economic Development Corp. director Terry Lee said company officials attributed the decision to an inability to recruit needed employees to Rochester and better proximity to customers in the Indianapolis area. The Rochester Sentinel reported that a company co-owner had previously discussed plans for expanding on its eight-acre site in that city. Lee said some of the company's workers plan on transferring to the new location, with the move expected to happen by October. Rochester is about 75 miles north of Noblesville.
Hartford-based Aetna Inc. and Philadelphia-based Cigna Corp., the nation’s third- and fifth-largest health insurers respectively, have announced their departure from Indiana’s individual health insurance market.
A two-man Indianapolis firm is making a splash in the graphic design industry with a Web-based tool that allows designers unfamiliar with Apple Inc. software code to build applications for iPads and iPhones.
Baseball and football are both celebrated in shows at the National Art Museum of Sport.
The company clearly is on a nice run, with seven straight quarters of increasing same-store sales and increasing earnings per share.
About 40 percent of the tickets sold during the Palladium’s first half-season went to subscribers, prompting managers to expand the series offerings for the full season that begins later this month.